IDXX vs QDEL
Idexx Laboratories Inc. /DE and QuidelOrtho Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | IDXX | QDEL |
|---|---|---|
| Revenue | $4.3B | $2.7B |
| Net income | $1.1B | $-1.1B |
| Gross margin | 61.8% | — |
| Net margin | 24.6% | −41.5% |
| Return on equity | 66.2% | −46.1% |
| Diluted EPS | $13.08 | −$16.69 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $1.1B | $-83.0M |
| Equity | $1.6B | $1.9B |
| Net debt / equity | 0.17× | 1.41× |
| Current ratio | 1.23× | 1.50× |
| Revenue CAGR 5y | 9.7% | 10.4% |
| Profit CAGR 5y | 12.7% | — |
IDXX bills 1.6× the revenue of QDEL, and QDEL closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | IDXX | QDEL |
|---|---|---|
| FY2025 | $4.3B | $2.7B |
| FY2024 | $3.9B | $2.8B |
| FY2023 | $3.7B | $3.0B |
| FY2022 | $3.4B | $3.3B |
| FY2021 | $3.2B | $1.7B |
| FY2020 | $2.7B | $1.7B |
Net income by year
Bottom line
| Fiscal year | IDXX | QDEL |
|---|---|---|
| FY2025 | $1.1B | $-1.1B |
| FY2024 | $887.9M | $-2.1B |
| FY2023 | $845.0M | $-10.1M |
| FY2022 | $679.1M | $548.7M |
| FY2021 | $744.8M | $704.2M |
| FY2020 | $581.8M | $810.3M |
Advertisement
AdSense · Rectangle 336×280
More in this industry